Floatz logo

[14c]-a4250

Alagille Syndrome

AlbireoPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Alagille Syndrome cohort.

Asset / SponsorPhaseRating
lum001
Mirum Pharmaceuticals, Inc.
Phase 2BBB
Lipitor
Children's Hospital of Fudan University
Phase 4BB
ODEVIXIBAT
Albireo
Phase 1CCC
Questran
Albireo
Phase 1CC
Cholestyramine
Albireo
Phase 1CC

Same molecule, other indications

[14c]-a4250 is also rated in:

cholestasisDormant
CC
Indicative ·
47 / 100
View asset →
progressive familial intrahepatic cholestasisDormant
CC
Indicative ·
47 / 100
View asset →
primary biliary cholangitisDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →